Korro Bio Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Korro Bio Inc
Access all reports
Korro Bio Inc. is a biopharmaceutical company engaged in the field of RNA editing to develop new genetic medicines. The company's innovative approach, leveraging the Oligonucleotide Promoted Editing of RNA (OPERA) platform, aims to harness natural processes for making transient, reversible changes to genetic instructions. This technology seeks to offer potential treatments for patients with rare and highly prevalent diseases by overcoming the complexities of earlier gene-editing methods. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Key slides for Korro Bio Inc
RBC Capital Markets Global Healthcare Conference
Korro Bio Inc
Corporate Presentation
Korro Bio Inc
Latest articles
Prada: The Story of an Icon
Prada's journey from a small Milan boutique to a global luxury empire, led by Miuccia's innovation and creativity.
5 Dec 2024
Hims & Hers: Bridging Gaps in Telehealth
Hims & Hers was founded in 2016 by Andrew Dudum and has grown into a ~$4 billion company in the telehealth industry in less than a decade.
5 Dec 2024
Andrew Dudum: Founder and CEO of Hims & Hers
Andrew Dudum is the founder and CEO of Hims & Hers, an innovative telehealth company focused on bridging the gap between consumers and healthcare.
4 Dec 2024
Ticker symbol
KRRO
Country
🇺🇸 United States